Byooviz

Bio & Pharma Samsung Bioepis gets FDA OK for its interchangeable biosimilar

Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official design...

Bio & Pharma Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...

Biosimilars Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz

Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...